Skip to main content

AlphaGene, Wayne State Partner to Study Brain Tumors

NEW YORK, Sept 11 – AlphaGene of Woburn, Mass., said Tuesday it has signed an agreement with Wayne State University to study malignant brain tumor cell types using gene expression technology.

Under the terms of the deal, AlphaGene will contribute its expertise in functional genomics, while Wayne State University will provide its research capabilities. Financial terms of the deal were not disclosed.

AlphaGene and Wayne State will also look to correlate gene expression patterns with treatment regimens and aim to develop new diagnostic and prognostic methods.

"We believe that by combining our technologies and expertise, we will gain a better insight into the genetic causes of the disease, and in so doing, we will identify new validated drug targets and markers for these difficult to treat brain tumors,” Donald McCarren, president and CEO of AlphaGene, said in a statement.

Wayne State University is currently developing a bank of brain tumors and normal blood specimens from consenting patients.

AlphaGene is a biotechnology company conducting research relating to neuro-degenerative diseases and cancer.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.